Drug efflux by Breast Cancer Resistance Protein (BCRP) is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924

BACKGROUND: Preclinical investigations have identified insulin-like growth factor (IGF) signaling as a key mechanism for cancer growth and resistance to clinically useful therapies in multiple tumor types, including breast cancer. Thus, agents targeting and blocking IGF signaling have promise in the...

Full description

Saved in:
Bibliographic Details
Main Authors: Hou, Xiaonan, Huang, Fei, Carboni, Joan M., Flatten, Karen, Asmann, Yan W., Eyck, Cynthia Ten, Nakanishi, Takeo, Tibodeau, Jennifer D., Ross, Douglas D., Gottardis, Marco M., Erlichman, Charles, Kaufmann, Scott H., Haluska, Paul
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3057506/
https://ncbi.nlm.nih.gov/pubmed/21220496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0438
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items